<DOC>
	<DOCNO>NCT01364922</DOCNO>
	<brief_summary>The primary purpose study evaluate analgesic effect safety hydrocodone/acetaminophen extend release compare placebo .</brief_summary>
	<brief_title>Phase 2 Chronic Low Back Pain Study</brief_title>
	<detailed_description>This phase 2 , multicenter , double-blind ( DB ) , placebo-controlled , randomize withdrawal study compare analgesic efficacy safety hydrocodone/acetaminophen extend release placebo subject moderate moderately severe chronic lower back pain ( CLBP ) . Participants meet pre-defined criterion conclusion open-label ( OL ) Titration Period proceed randomization double-blind ( DB ) Maintenance Period study . Study drug give total approximately 5 week , include 2 week OL , 2 week DB , 3-day taper . During OL period , participant take increase dos hydrocodone/acetaminophen extend release take 2 tablet , twice daily . During DB period , participant hydrocodone/acetaminophen extended release group take 1 hydrocodone/acetaminophen extend release tablet twice daily throughout 2 week , participant placebo group take 1 placebo tablet twice daily .</detailed_description>
	<mesh_term>Back Pain</mesh_term>
	<mesh_term>Low Back Pain</mesh_term>
	<mesh_term>Hydrocodone</mesh_term>
	<mesh_term>Acetaminophen , hydrocodone drug combination</mesh_term>
	<mesh_term>Oxycodone</mesh_term>
	<mesh_term>Acetaminophen</mesh_term>
	<criteria>Adult subject diagnosis chronic low back pain least 6 month duration Subjects history surgical invasive intervention</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>